Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.
about
PPAR-gamma: Therapeutic Potential for Multiple SclerosisPPARs and the cardiovascular systemCyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivationPPAR-γ -- a possible drug target for complicated pregnanciesRole of lipotoxicity in endothelial dysfunctionPeroxisome Proliferator-Activated Receptor- γ in Thyroid AutoimmunityMicroarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis.Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation.Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis.NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathwayPeroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damageVLDL hydrolysis by hepatic lipase regulates PPARδ transcriptional responsesInhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance.Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation.Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1The role of chemokines in atherosclerosis.Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update.Network analysis identifies a putative role for the PPAR and type 1 interferon pathways in glucocorticoid actions in asthmaticsInterferon-gamma induces retinoic acid-inducible gene-I in endothelial cells.Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts.Peroxisome proliferator-activated receptor gamma and atherosclerosis.Role of CXCL1 in tumorigenesis of melanoma.Vascular effects of GI262570X (PPAR-gamma agonist) in the brown adipose tissue of Han Wistar rats: a review of 1-month, 13-week, 27-week and 2-year oral toxicity studies.Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial CellsEffects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation.The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria.Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.PPARgamma as a new therapeutic target in inflammatory bowel diseasesPPARalpha in atherosclerosis and inflammation.Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.Bexarotene in the treatment of cutaneous T-cell lymphoma.Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesAntineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells.Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism.Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques.
P2860
Q21342822-342634B7-8D52-4699-BFD3-EAC63CDF5967Q24642728-DDA5E360-25CD-4BAF-ADE3-A1E6C623132DQ24684054-B2CD6757-5785-4AC3-A210-D3610D2E7A86Q26863678-E4953CB4-46AB-4767-AC6F-792E48F616A2Q27000731-23CEE8BF-C379-4A3D-985C-3CAEE2FC8366Q27022369-3A8EA943-A35A-4281-B9F8-F1CA70E8ADF5Q33243924-CD692616-44E3-4C85-A535-16EA408ACD40Q33406281-42C50243-8877-4CA4-853F-E12BA5FD4EADQ33642053-FFDC728F-DB4D-4FFA-8FDD-DBCDC41B0420Q33644094-4C9FC0E2-10FF-45F4-8A7E-C40D6FCF9873Q33746963-2688F594-404B-49CC-A501-977BD394AA0FQ33815718-9A63C16C-5F60-4FCE-B8C2-6EEAA6433BB5Q33816291-B56058B9-78F0-4F10-808F-9CD1E309B7D1Q33959265-1082AEA5-96F0-41BE-8C2C-2507D42812F0Q33967999-F63F1514-D9AA-4D72-8678-9F60650E50AAQ34024668-45B2D9CC-040C-442C-88B8-9918F64D9FFAQ34075896-E5C53382-4499-4E11-B10D-C3C0AFD8F5DEQ34178976-6D69EE8C-796E-4B3B-B848-3E5232293D3DQ34207434-85CA5C08-4DE7-4EBC-B621-D5C667018A7FQ34290988-569E0CC1-AF50-4A19-B9FB-EB11ED39B640Q34309219-8BB8528B-5438-4E28-AA49-4D3D1E6A4AD0Q34348648-DC44344D-F203-446D-8D1F-65F10431B57EQ34365179-C638EC3F-2ED9-4C7A-B7DD-0099DE1730DAQ34492831-59EE24CF-E9D2-4B06-AF4A-B30606A80779Q34724089-87D3A672-7A4E-450D-AF8E-2297D4DED912Q34790065-8B26D818-1BE8-4377-9AF3-D66A9A8157ECQ34962291-58A6A611-1974-44F9-AADE-47E90B1D2533Q35014033-AB550545-7F56-4893-8ADC-88D572C84C89Q35044388-3C2FFB23-76BA-4334-8C99-F086A7D90491Q35101529-A14D79F8-6098-4D29-84DC-6276F5584410Q35747641-ED44A9C3-BB2F-4705-A5E8-969ED764DFCFQ35768913-233D845C-729C-47F4-B7C1-B44FE73D3815Q36154953-77CF0A10-0822-434A-AC44-F000395D2792Q36393212-75D0A1D7-2789-48F0-A33F-6B1FA7B728BAQ36458462-844201DB-BD9C-49CA-ADC8-32B37E641D02Q36510633-5C0534DD-923F-4845-B494-A8302158B6C3Q36536205-430ED96C-4102-401A-8007-2501B07C43CEQ36611745-E420025E-EB37-46F7-A256-319A40B7578BQ36632030-A4DB0735-8F34-4704-9A0A-28EE6CF37D1FQ36634314-D4D14547-07B9-489E-A8BD-91526D603635
P2860
Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@ast
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@en
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@nl
type
label
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@ast
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@en
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@nl
prefLabel
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@ast
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@en
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@nl
P2093
P2860
P1476
Peroxisome proliferator-activa ...... AC in human endothelial cells.
@en
P2093
A D Luster
M N Sarafi
R M Ransohoff
P2860
P304
P356
10.4049/JIMMUNOL.164.12.6503
P407
P577
2000-06-01T00:00:00Z